gastroesophageal cancer (Cancer)
Information
- Disease name
- gastroesophageal cancer
- Disease ID
- DOID:0080374
- Description
- "A gastrointestinal system cancer that is located_in the proximal esophagus and the distal stomach." [url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042434]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
| NCT04294784 | Active, not recruiting | Phase 2 | Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | April 3, 2020 | June 30, 2023 |
| NCT04544046 | Active, not recruiting | N/A | Supportive Oncology Care At Home RCT | September 16, 2020 | December 31, 2024 |
| NCT03279237 | Active, not recruiting | Phase 1 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | October 24, 2017 | September 2023 |
| NCT04504669 | Active, not recruiting | Phase 1 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | August 18, 2020 | January 31, 2025 |
| NCT03490292 | Active, not recruiting | Phase 1/Phase 2 | Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer | May 29, 2018 | March 2023 |
| NCT03490565 | Active, not recruiting | N/A | PREoperativ Study of Exercise Training | August 16, 2018 | December 31, 2028 |
| NCT03610711 | Active, not recruiting | Phase 1/Phase 2 | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | March 6, 2019 | April 2025 |
| NCT04164979 | Active, not recruiting | Phase 2 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | February 4, 2020 | December 30, 2024 |
| NCT03044613 | Active, not recruiting | Phase 1 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | July 11, 2017 | February 2025 |
| NCT03647969 | Active, not recruiting | Phase 2 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | November 7, 2018 | March 2024 |
| NCT04363801 | Active, not recruiting | Phase 2 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | July 29, 2020 | December 2025 |
| NCT06138223 | Active, not recruiting | N/A | The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES) | October 1, 2023 | September 30, 2028 |
| NCT03798626 | Active, not recruiting | Phase 1 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | May 22, 2019 | December 30, 2024 |
| NCT04681248 | Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | |||
| NCT03720678 | Completed | Phase 1 | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | November 18, 2018 | June 25, 2021 |
| NCT03775850 | Completed | Phase 1 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | December 19, 2018 | October 31, 2021 |
| NCT03321630 | Completed | Phase 2 | A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies | October 24, 2017 | January 16, 2024 |
| NCT00525915 | Completed | Phase 2 | Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma | April 2005 | March 2013 |
| NCT00673673 | Completed | Phase 2 | FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer | May 2008 | July 2014 |
| NCT00718354 | Completed | Phase 3 | Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT | July 2008 | August 2010 |
| NCT01611857 | Completed | Phase 1/Phase 2 | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | July 2012 | August 2015 |
| NCT01715233 | Completed | Phase 2 | Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. | December 2012 | April 2017 |
| NCT02013154 | Completed | Phase 1 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | May 5, 2014 | January 11, 2021 |
| NCT02317991 | Completed | Phase 2 | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | May 5, 2015 | May 21, 2021 |
| NCT02586987 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | December 28, 2015 | September 20, 2019 |
| NCT02853474 | Completed | Phase 3 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | October 2016 | December 2022 |
| NCT03165994 | Completed | Phase 2 | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | October 6, 2017 | February 21, 2023 |
| NCT03409848 | Completed | Phase 2 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma | March 1, 2018 | March 5, 2022 |
| NCT03416244 | Completed | Phase 2 | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer | February 21, 2018 | November 19, 2021 |
| NCT03472365 | Completed | Phase 2 | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | April 2, 2018 | November 25, 2020 |
| NCT03629756 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | July 24, 2018 | September 3, 2021 |
| NCT03829436 | Completed | Phase 1 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | March 20, 2019 | September 7, 2022 |
| NCT04074343 | Completed | Phase 1 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | August 26, 2019 | July 21, 2022 |
| NCT04099641 | Completed | Phase 2 | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | September 11, 2019 | October 26, 2022 |
| NCT06241469 | Not yet recruiting | Phase 2 | Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study | February 3, 2024 | February 2, 2027 |
| NCT05431738 | Not yet recruiting | N/A | Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) | September 1, 2022 | September 1, 2025 |
| NCT06283238 | Not yet recruiting | Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) | June 17, 2024 | March 25, 2027 | |
| NCT06410534 | Not yet recruiting | Phase 2 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | June 23, 2024 | September 1, 2032 |
| NCT06422403 | Not yet recruiting | Phase 2 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | July 1, 2024 | December 31, 2029 |
| NCT06028737 | Recruiting | Phase 2/Phase 3 | Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | August 25, 2023 | December 2031 |
| NCT04069273 | Recruiting | Phase 2 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | December 1, 2020 | December 10, 2025 |
| NCT04688801 | Recruiting | N/A | Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer | July 1, 2020 | December 31, 2027 |
| NCT05098132 | Recruiting | Phase 1 | Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors | January 25, 2022 | October 2025 |
| NCT05122091 | Recruiting | Phase 2 | Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma | November 5, 2021 | November 30, 2024 |
| NCT05205343 | Recruiting | Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers | May 11, 2022 | May 31, 2024 | |
| NCT05338060 | Recruiting | A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer | January 26, 2022 | January 30, 2025 | |
| NCT05379972 | Recruiting | Phase 2 | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | January 12, 2023 | December 2028 |
| NCT05427487 | Recruiting | Phase 1 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | February 17, 2023 | September 1, 2024 |
| NCT05438940 | Recruiting | N/A | Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients | July 15, 2022 | July 2024 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT05644431 | Recruiting | GastrOesophageal Tumor, Immune Microenvionnment (GOTIM) | July 19, 2023 | January 15, 2028 | |
| NCT05717998 | Recruiting | Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy | April 2, 2021 | December 31, 2025 | |
| NCT05924789 | Recruiting | Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America | August 11, 2023 | June 17, 2024 | |
| NCT06109467 | Recruiting | Phase 2 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | January 12, 2024 | April 2028 |
| NCT06171789 | Recruiting | Phase 1/Phase 2 | PRO1107 in Patients With Advanced Solid Tumors | January 29, 2024 | February 2027 |
| NCT06239194 | Recruiting | Phase 1/Phase 2 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | June 12, 2024 | February 2029 |
| NCT06243757 | Recruiting | A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers | January 8, 2024 | January 8, 2036 | |
| NCT06356311 | Recruiting | Phase 3 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | May 3, 2024 | May 5, 2028 |
| NCT00080002 | Terminated | Phase 2 | Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction | December 2003 | |
| NCT03125200 | Terminated | Phase 1 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | May 18, 2017 | April 5, 2018 |
| NCT04510285 | Terminated | Phase 2 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | August 10, 2020 | December 30, 2022 |
| NCT02669914 | Terminated | Phase 2 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | September 12, 2016 | January 11, 2018 |
| NCT01145404 | Terminated | Phase 2 | Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | June 2010 | October 2013 |
| NCT00256269 | Terminated | Phase 2 | Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma | June 2005 | February 7, 2007 |
| NCT03997448 | Terminated | Phase 2 | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | August 26, 2019 | January 30, 2020 |
| NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
| NCT04555304 | Unknown status | Phase 2 | Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | September 15, 2020 | January 15, 2022 |
| NCT04281576 | Unknown status | N/A | Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | December 19, 2019 | September 2021 |
| NCT03949907 | Unknown status | N/A | Early IntraVenous Administration of Nutritional Support | April 14, 2020 | October 30, 2023 |
| NCT04385641 | Unknown status | N/A | Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer | October 8, 2019 | October 8, 2022 |
| NCT03013010 | Unknown status | Phase 3 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy | December 2016 | December 2023 |
| NCT03613142 | Unknown status | N/A | Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy | January 1, 2019 | December 30, 2021 |
| NCT03813784 | Unknown status | Phase 3 | A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer | March 7, 2019 | March 2023 |
| NCT04602117 | Withdrawn | Phase 1 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | July 28, 2021 | November 17, 2021 |
| NCT03818997 | Withdrawn | Phase 2 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | December 2019 | April 2022 |
- Disase is a (Disease Ontology)
- DOID:3119